Roche's Giredestrant Combination Meets Phase III Endpoints in Advanced Breast Cancer
核心洞察
Roche's phase III evERA study demonstrated that giredestrant plus everolimus significantly improved progression-free survival in ER-positive advanced breast cancer patients previously treated with CDK 4/6 inhibitors.
The all-oral combination met both co-primary endpoints in intention-to-treat and ESR1 (搜索)-mutated populations, marking the first positive head-to-head phase III trial of a selective estrogen receptor degrader regimen versus standard care.
The treatment was well tolerated with no new safety signals observed, and Roche plans to submit data to regulatory authorities to bring this potential therapy to patients.
Roche announced positive results from its phase III evERA study evaluating investigational giredestrant in combination with everolimus for patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2 (搜索))-negative, locally advanced or metastatic breast cancer who had previously received cyclin-dependent kinase (CDK) 4/6 inhibitor and endocrine therapy.
The study met both co-primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in both the intention-to-treat and ESR1 (搜索)-mutated populations compared with standard-of-care endocrine therapy plus everolimus. Overall survival data were immature, but showed a clear positive trend, with follow-up continuing to the next analysis.
"These results show that the giredestrant combination provided a meaningful benefit for ER-positive breast cancer patients whose disease has progressed following treatment with a CDK inhibitor," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development. "We look forward to discussing these results with regulatory authorities with the goal of making this giredestrant-based regimen available to many people with advanced ER-positive breast cancer."
First-in-Class Achievement
The evERA study represents the first positive head-to-head phase III trial investigating an all-oral selective estrogen receptor degrader-containing regimen versus a standard of care combination. The giredestrant combination was well tolerated, with adverse events consistent with the known safety profiles of the individual study treatments and no new safety signals observed.
Addressing Treatment Resistance
ER-positive breast cancer accounts for approximately 70% of breast cancer cases. Despite treatment advances, this subtype remains particularly challenging to treat due to its biological complexity. Resistance to endocrine therapies, particularly in the post-CDK inhibitor setting, increases the risk of disease progression and is associated with poor outcomes.
In the post-CDK inhibitor setting, up to 40% of people with ER-positive disease have ESR1 (搜索) mutations. The evERA trial was enriched for ESR1-mutated patients above the natural prevalence to assess efficacy in this population specifically.
Study Design and Endpoints
The evERA Breast Cancer study (NCT05306340) is a phase III, randomized, open-label, multicentre study comparing giredestrant in combination with everolimus versus standard-of-care endocrine therapy in combination with everolimus.
The co-primary endpoints were investigator-assessed progression-free survival in the intention-to-treat and ESR1 (搜索)-mutated populations, defined as the time from randomization to disease progression or death from any cause. Key secondary endpoints included overall survival, objective response rate, duration of response, clinical benefit rate and safety.
Mechanism of Action
Giredestrant is an investigational, oral, next-generation selective estrogen receptor degrader (SERD) and full antagonist. The drug is designed to block estrogen from binding to the estrogen receptor, triggering its breakdown and stopping or slowing down the growth of cancer cells.
Combination therapies, such as giredestrant plus everolimus, could address treatment resistance by targeting two different signaling pathways, with the potential for improved patient outcomes. Additionally, as an all-oral combination, this regimen could help minimize the impact of treatment on people's lives without the need for injections.
Comprehensive Development Program
Giredestrant has an extensive clinical development program spanning five company-sponsored phase III clinical trials across multiple treatment settings and lines of therapy, including adjuvant treatment in early-stage breast cancer, first-line metastatic disease, and various combination approaches with CDK 4/6 inhibitors and HER2 (搜索)-targeted therapies.
Data from the evERA study will be presented at an upcoming medical meeting and submitted to health authorities with the view of bringing this potential treatment option to patients as soon as possible.